Dendreon and InterMune: Do They Mean Anything for the Regulatory Climate at FDA?
This article was originally published in RPM Report
Executive Summary
Provenge and pirfenidone were two of the most closely watched pending applications at FDA. The agency's decision on the two therapies may offer some insight into the current regulatory climate.